Puma Biotechnology (PBYI) EBT Margin (2017 - 2025)
Historic EBT Margin for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to 16.97%.
- Puma Biotechnology's EBT Margin fell 86200.0% to 16.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.58%, marking a year-over-year increase of 44600.0%. This contributed to the annual value of 10.46% for FY2024, which is 8300.0% up from last year.
- Per Puma Biotechnology's latest filing, its EBT Margin stood at 16.97% for Q3 2025, which was down 86200.0% from 11.76% recorded in Q2 2025.
- In the past 5 years, Puma Biotechnology's EBT Margin ranged from a high of 25.59% in Q3 2024 and a low of 96.52% during Q3 2021
- In the last 5 years, Puma Biotechnology's EBT Margin had a median value of 7.1% in 2025 and averaged 1.01%.
- Its EBT Margin has fluctuated over the past 5 years, first plummeted by -345300bps in 2021, then soared by 960100bps in 2022.
- Puma Biotechnology's EBT Margin (Quarter) stood at 8.01% in 2021, then plummeted by -176bps to 6.06% in 2022, then skyrocketed by 393bps to 17.74% in 2023, then grew by 17bps to 20.72% in 2024, then dropped by -18bps to 16.97% in 2025.
- Its last three reported values are 16.97% in Q3 2025, 11.76% for Q2 2025, and 7.1% during Q1 2025.